Overview

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Phase:
PHASE2
Details
Lead Sponsor:
TORL Biotherapeutics, LLC
Collaborator:
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Treatments:
pegfilgrastim
Pharmaceutical Preparations